6 Ways to Maximize Product Value as Loss of Exclusivity Approaches

Loss of exclusivity doesn’t mean the end of the income stream for branded drugs. Here’s how drug companies can mitigate the effects of drug patent expiration.
The post 6 Ways to Maximize Product Value as Loss of Exclusivity Approaches appeared first on…


DrugPatentWatch Alternatives

Considering switching to DrugPatentWatch? See why others have come to us. Switch to DrugPatentWatch
The post DrugPatentWatch Alternatives appeared first on DrugPatentWatch – Make Better Decisions.


Review of Drugs Approved via the 505(b)(2) Pathway: Uncovering Drug Development Trends and Regulatory Requirements

This paper was originally published by Ingrid Freije, Stéphane Lamouche, and Mario Tanguay in Therapeutic Innovation & Regulatory Science under a Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/…


Generic Drug Market Entry in Europe: Why a Tailored Approach Is Best

Generic drug makers must tailor European market entry strategies to each country. Moreover, they must address the sequence in which they want to enter markets.
The post Generic Drug Market Entry in Europe: Why a Tailored Approach Is Best appeared first…


Which generic companies have the most drugs?

This chart shows the pharmaceutical companies with the most generic drugs. Companies that excel in generic drug development tend to also be very good at patent challenge and at developing…
The post Which generic companies have the most drugs? appeared …


Which pharmaceutical companies have the most SPCs in Netherlands?

This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Netherlands. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating…
The post Which pharmaceut…


Do NOT follow this link or you will be banned from the site!